Visceral Leishmaniasis (VL) is the most fatal form of disease leishmaniasis. To date, there
are no effective prophylactic measures and therapeutics available against VL. Recently, new …

Leptin, a pleiotropic protein has long been recognized to play an important role in the
regulation of energy homeostasis, metabolism, neuroendocrine function, and other …

Leishmaniasis remains a major public health problem worldwide and is classified as
Category I by the TDR/WHO, mainly due to the absence of control. Many experimental …

The outcomes of Leishmania infection are determined by host immune and nutrition status,
parasite species, and co-infection with other pathogens. While subclinical infection and self …

A key point of immunity against protozoan Leishmania parasites is the development of an
optimal T cell response, which includes a low apoptotic rate, high proliferative activity and …

In mammals subverted as hosts by protozoan parasites, the latter and/or the agonists they
release are detected and processed by sensors displayed by many distinct immune cell …

Leishmania infantum causes a chronic infectious disease named visceral leishmaniasis
(VL). We employed a non-human primate model to monitor immune parameters over time …

Background With the paucity of new drugs and HIV co-infection, vaccination remains an
unmet research priority to combat visceral leishmaniasis (VL) requiring strong cellular …

Leishmania donovani is a parasite that causes visceral leishmaniasis by infecting and
replicating in macrophages of the bone marrow, spleen, and liver. Severe anemia and …

Immuno-modulators in combination with antileishmanial drug miltefosine is a better
therapeutic approach for treatment of Visceral Leishmaniasis (VL) as it not only reduces the …